Compare VGZ & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VGZ | CABA |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.7M | 319.6M |
| IPO Year | 1996 | 2019 |
| Metric | VGZ | CABA |
|---|---|---|
| Price | $2.10 | $3.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $3.75 | ★ $14.50 |
| AVG Volume (30 Days) | 1.1M | ★ 4.3M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.91 | $1.26 |
| 52 Week High | $3.13 | $4.23 |
| Indicator | VGZ | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 50.47 |
| Support Level | $1.95 | $2.17 |
| Resistance Level | $2.42 | $3.54 |
| Average True Range (ATR) | 0.11 | 0.34 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 19.74 | 38.15 |
Vista Gold Corp operates as a development-stage company in the gold mining industry. Its flagship asset is the Mt Todd Gold Project, a development-stage gold deposit located in the Tier-1 jurisdiction of Northern Territory, Australia. Mt Todd offers a large gold mineral reserve, development optionality, expansion opportunities, exploration upside, local infrastructure, community support, and demonstrated economic feasibility. It operates in one reportable segment, consisting of acquisition, exploration and evaluation activities which are focused on Australia.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.